A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma

Click to increase image sizeClick to decrease image size Disclosure statementSES: research funding: Genentech, Janssen, Pharmacyclics, Bristol Meyers/Celgene, Merck, Gilead Sciences, Acerta Pharma, BeiGene, Genmab, Incyte, and Morphosys. Consultancy: Genetech Advisory Board: Astra Zeneca and Janssen. RTM: research funding: BMS, Novartis, and Orca Bio. Consultant services: CRISPR Therapeutics, Incyte, Novartis, Bristol-Myers Squibb/Celgene, Allovir, and Gilead/Kite. Scientific Advisory Board: Artiva Therapeutics. DSMB membership: Novartis, Athersys, Vor Pharma, and Century Therapeutics. AC: clinical trial funding: Novartis, Fate Therapeutics, and AstraZeneca. Consultancy: Kite, Intellia Therapeutics, and Elsevier. AV: clinical trial funding: Genmab, Genentech, and ADC Therapeutics.Additional informationFundingThis work was funded by the Knight Cancer Institute’s Leukemia and Lymphoma Distinguished Scholar Fund.